I believe Cyclin-Dependent Kinase 9 (CDK9) inhibitors are one modality that will bring us a step closer to that future. By targeting the fundamental processes that enable cancer cell survival ...
WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an investigational CDK9 inhibitor, at the 66th American Society of ...
SELLAS Life Sciences Group, Inc. announced promising results from a Phase 2a trial of their CDK9 inhibitor, SLS009 (tambiciclib), in combination with the BTK inhibitor zanubrutinib for patients ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback